Sugi Predict

Sugi Predict / Compounds / SCHEMBL1020404

SCHEMBL1020404

SCHEMBL1020404

Clc1cc(Br)cc2[nH]ccc12

nearest known ligand 0.50

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
▸ RHEB Q15382 8/20 0.50
▸ CSNK2A1 P68400 1/20 0.46
▸ AHR P35869 5/20 0.45
▸ ALDH1A1 P00352 1/20 0.41
▸ HTR6 P50406 1/20 0.41
▸ NR4A2 P43354 2/20 0.41
▸ CYP2A6 P11509 1/20 0.41
▸ FBP1 P09467 1/20 0.39
▸ CMA1 P23946 1/20 0.36
▸ F7 P08709 1/20 0.36
▸ LTA4H P09960 1/20 0.36
▸ F3 P13726 1/20 0.36
▸ SYK P43405 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29506983 1.00 RHEB (0.50) RHEBCSNK2A1AHRALDH1A1HTR6
SCHEMBL15826435 0.79 RHEB (0.50) RHEBCSNK2A1AHRALDH1A1NR4A2
SCHEMBL29531208 0.78 RHEB (0.58) RHEBCSNK2A1AHRALDH1A1NR4A2
SCHEMBL1022450 0.78 RHEB (0.58) RHEBCSNK2A1AHRALDH1A1NR4A2
SCHEMBL1020056 0.78 AHR (0.54) RHEBCSNK2A1AHRALDH1A1HTR6
SCHEMBL29644241 0.78 AHR (0.54) RHEBCSNK2A1AHRALDH1A1HTR6
SCHEMBL25383240 0.75 AHR (0.45) RHEBCSNK2A1AHRALDH1A1HTR6
SCHEMBL1019925 0.75 AHR (0.45) RHEBCSNK2A1AHRALDH1A1HTR6
SCHEMBL1021334 0.75 AHR (0.45) RHEBCSNK2A1AHRALDH1A1HTR6
SCHEMBL29507054 0.75 AHR (0.45) RHEBCSNK2A1AHRALDH1A1HTR6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025245484-A1 FOXN1 ACTIVATORS THYMOFOX INC. (US) 2025-11-27 — — WO disclosed
WO-2024263860-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY IFM DUE, INC. (US) 2024-12-26 — — WO disclosed
CN-118459452-B PolyADP ribose hydrolase inhibitor and application thereof 苏州国匡医药科技有限公司 2024-10-25 — — CN disclosed
CN-118459452-A PolyADP ribose hydrolase inhibitor and application thereof 苏州国匡医药科技有限公司 2024-08-09 — — CN disclosed
US-20240076285-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY NOVARTIS PHARMA AG (CH) 2024-03-07 — — US disclosed
CN-117222634-A Compounds and compositions for the treatment of diseases associated with STING activity 艾福姆德尤股份有限公司 2023-12-12 — — CN disclosed
US-20230374007-A1 COMPOUNDS AND THEIR USE IN TREATING CANCER ASTRAZENECA AB (SE) 2023-11-23 — — US disclosed
US-20230374007-A1 COMPOUNDS AND THEIR USE IN TREATING CANCER ASTRAZENECA AB (SE) 2023-11-23 — — US disclosed
EP-4263523-A2 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY IFM Due, Inc. (US) 2023-10-25 — — EP disclosed
CN-116249554-A Compounds and their use in the treatment of cancer 阿斯利康(瑞典)有限公司 2023-06-09 — — CN disclosed
US-20130197046-A1 NOVEL P2X7R ANTAGONISTS AND THEIR USE AFFECTIS PHARMACEUTICALS AG (DE) 2013-08-01 — — US disclosed
WO-2012163456-A1 NOVEL P2X7R ANTAGONISTS AND THEIR USE AFFECTIS PHARMACEUTICALS AG (DE) 2012-12-06 — — WO disclosed
WO-2012163792-A1 NOVEL P2X7R ANTAGONISTS AND THEIR USE AFFECTIS PHARMACEUTICALS AG (DE) 2012-12-06 — — WO disclosed
US-20120302597-A1 NOVEL P2X7R ANTAGONISTS AND THEIR USE AFFECTIS PHARMACEUTICALS AG (DE) 2012-11-29 — — US disclosed
US-8232290-B2 P2X7R antagonists and their use AFFECTIS PHARMACEUTICALS AG (DE) 2012-07-31 — — US disclosed
CN-102046240-A Novel P2X7R antagonists and their use AFFECTIS PHARMACEUTICALS AG 2011-05-04 — — CN disclosed
EP-2105164-B1 Novel P2X7R antagonists and their use AFFECTIS PHARMACEUTICALS AG (DE) 2011-01-12 — — EP disclosed
US-20090312366-A1 NOVEL P2X7R ANTAGONISTS AND THEIR USE AFFECTIS PHARMACEUTICALS AG (DE) 2009-12-17 — — US disclosed
WO-2009118175-A1 NOVEL P2X7R ANTAGONISTS AND THEIR USE AFFECTIS PHARMACEUTICALS AG (DE) 2009-10-01 — — WO disclosed
EP-2105164-A1 Novel P2X7R antagonists and their use Affectis Pharmaceuticals AG (DE) 2009-09-30 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240076285-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY STING1, CGAS, IRF3 RHEB 1004/4885CSNK2A1 694/4885AHR 2635/4885
US-20230374007-A1 COMPOUNDS AND THEIR USE IN TREATING CANCER RARA, RARG, RARB RHEB 1148/4885CSNK2A1 3204/4885AHR 465/4885
US-20130197046-A1 NOVEL P2X7R ANTAGONISTS AND THEIR USE P2RX3, P2RX7, P2RX2 RHEB 4753/4885CSNK2A1 2599/4885AHR 328/4885
US-20120302597-A1 NOVEL P2X7R ANTAGONISTS AND THEIR USE P2RX3, P2RX7, P2RX2 RHEB 4753/4885CSNK2A1 2599/4885AHR 328/4885
US-20090312366-A1 NOVEL P2X7R ANTAGONISTS AND THEIR USE P2RX3, P2RX7, P2RX2 RHEB 4753/4885CSNK2A1 2599/4885AHR 328/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.